Related references
Note: Only part of the references are listed.Efficacy of recombinant erythropoietin in autoimmune hemolytic anemia: a multicenter international study
Bruno Fattizzo et al.
HAEMATOLOGICA (2021)
Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients (Pts) with Very High/High-Risk Myelodysplastic Syndrome (vHR/HRMDS) and Acute Myeloid Leukemia (AML): Final Analysis from a Phase Ib Study
Andrew M. Brunner et al.
BLOOD (2021)
Personalized Prediction Model to Risk Stratify Patients With Myelodysplastic Syndromes
Aziz Nazha et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Hypoplastic Myelodysplastic Syndromes: Just an Overlap Syndrome?
Bruno Fattizzo et al.
CANCERS (2021)
Clinical and prognostic significance of small paroxysmal nocturnal hemoglobinuria clones in myelodysplastic syndrome and aplastic anemia
Bruno Fattizzo et al.
LEUKEMIA (2021)
Large Granular Lymphocyte Expansion in Myeloid Diseases and Bone Marrow Failure Syndromes: Whoever Seeks Finds
Bruno Fattizzo et al.
FRONTIERS IN ONCOLOGY (2021)
Somatic mutations in lymphocytes in patients with immune-mediated aplastic anemia
Sofie Lundgren et al.
LEUKEMIA (2021)
Autoimmune Complications in Hematologic Neoplasms
Wilma Barcellini et al.
CANCERS (2021)
Mutation status and burden can improve prognostic prediction of patients with lower-risk myelodysplastic syndromes
Lingxu Jiang et al.
CANCER SCIENCE (2020)
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes
Pierre Fenaux et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Therapeutic Targeting of the Macrophage Immune Checkpoint CD47 in Myeloid Malignancies
Mark P. Chao et al.
FRONTIERS IN ONCOLOGY (2020)
Myelodysplastic Syndromes
Mario Cazzola
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Clinical, histopathological and molecular characterization of hypoplastic myelodysplastic syndrome
Elisa Bono et al.
LEUKEMIA (2019)
Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials
U. Platzbecker et al.
BLOOD (2019)
Prognostic scoring systems for myelodysplastic syndromes (MDS) in a population-based setting: a report from the Swedish MDS register
Daniel Moreno Berggren et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Deep sequencing and flow cytometric characterization of expanded effector memory CD8+CD57+ T cells frequently reveals T-cell receptor Vβ oligoclonality and CDR3 homology in acquired aplastic anemia
Valentina Giudice et al.
HAEMATOLOGICA (2018)
Prognostic impact of ASXL1 mutations in patients with myelodysplastic syndromes and multilineage dysplasia with or without ring sideroblasts
Abhishek A. Mangaonkar et al.
LEUKEMIA RESEARCH (2018)
Deep sequencing and flow cytometric characterization of expanded effector memory CD8+CD57+ T cells frequently reveals T-cell receptor Vβ oligoclonality and CDR3 homology in acquired aplastic anemia
Valentina Giudice et al.
HAEMATOLOGICA (2018)
Paroxysmal nocturnal hemoglobinuria testing in patients with myelodysplastic syndrome in clinical practice-frequency and indications
S. A. Wong et al.
CURRENT ONCOLOGY (2018)
The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort
Maximilian Stahl et al.
BLOOD ADVANCES (2018)
Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial
Esther N. Oliva et al.
LANCET HAEMATOLOGY (2017)
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber et al.
BLOOD (2016)
Detection of erythroblast antibodies in mitogen-stimulated bone marrow cultures from patients with myelodysplastic syndromes
Anna Zaninoni et al.
TRANSFUSION (2016)
Treatment of low-risk myelodysplastic syndromes
Valeria Santini
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2016)
Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM)
M. G. Della Porta et al.
LEUKEMIA (2015)
Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes
I. Ganan-Gomez et al.
LEUKEMIA (2015)
Use of newer prognostic indices for patients with myelodysplastic syndromes in the low and intermediate-1 risk categories: a population-based study
David Valcarcel et al.
LANCET HAEMATOLOGY (2015)
Landscape of genetic lesions in 944 patients with myelodysplastic syndromes
T. Haferlach et al.
LEUKEMIA (2014)
Clinical and biological implications of driver mutations in myelodysplastic syndromes
Elli Papaemmanuil et al.
BLOOD (2013)
Revised International Prognostic Scoring System for Myelodysplastic Syndromes
Peter L. Greenberg et al.
BLOOD (2012)
Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes
Timothy A. Graubert et al.
NATURE GENETICS (2012)
Frequent pathway mutations of splicing machinery in myelodysplasia
Kenichi Yoshida et al.
NATURE (2011)
Somatic SF3B1 Mutation in Myelodysplasia with Ring Sideroblasts
E. Papaemmanuil et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Clinical Effect of Point Mutations in Myelodysplastic Syndromes
Rafael Bejar et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Comparison of hypoplastic myelodysplastic syndrome (MDS) with normo-/hypercellular MDS by International Prognostic Scoring System, cytogenetic and genetic studies
T-C Huang et al.
LEUKEMIA (2008)
Anti-erythroblast autoimmunity in early myelodysplastic syndromes
Wilma Barcellini et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2007)
Cyclosporin A in myelodysplastic syndrome: a preliminary report
A Dixit et al.
ANNALS OF HEMATOLOGY (2005)
Effects of cyclosporine on hematopoietic and immune functions in patients with hypoplastic myelodysplasia
C Selleri et al.
CANCER (2002)
Immunohematological findings in myelodysplastic syndrome
MCZ Novaretti et al.
ACTA HAEMATOLOGICA (2001)
Share Paper
